The PANCAID project envisions a world where pancreatic cancer is no longer a devastating disease with limited treatment options, but instead, a condition that can be detected and treated at an early stage. Through its groundbreaking research, PANCAID aims to revolutionize pancreatic cancer diagnosis by developing a minimally invasive blood test that can detect the disease at its earliest stages. This ambitious international research consortium brings together expertise from multiple fields, including oncology, molecular biology, bioinformatics, and clinical research, to provide a comprehensive and innovative approach to cancer diagnosis. By leveraging liquid biopsy diagnostics, PANCAID aims to advance our understanding of pancreatic cancer development, leading to improved treatment options, and ultimately, saving lives.
Early detection of pancreatic cancer through the development of a minimally invasive blood test